Daniel J. Figdore

479 total citations
17 papers, 213 citations indexed

About

Daniel J. Figdore is a scholar working on Physiology, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, Daniel J. Figdore has authored 17 papers receiving a total of 213 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Physiology, 8 papers in Psychiatry and Mental health and 3 papers in Molecular Biology. Recurrent topics in Daniel J. Figdore's work include Alzheimer's disease research and treatments (8 papers), Dementia and Cognitive Impairment Research (7 papers) and Frailty in Older Adults (2 papers). Daniel J. Figdore is often cited by papers focused on Alzheimer's disease research and treatments (8 papers), Dementia and Cognitive Impairment Research (7 papers) and Frailty in Older Adults (2 papers). Daniel J. Figdore collaborates with scholars based in United States. Daniel J. Figdore's co-authors include Alicia Algeciras‐Schimnich, Joshua A. Bornhorst, Ronald C. Petersen, Prashanthi Vemuri, Clifford R. Jack, David S. Knopman, Jonathan Graff‐Radford, Michelle M. Mielke, Val J. Lowe and Vijay K. Ramanan and has published in prestigious journals such as Brain, Neurology and Clinica Chimica Acta.

In The Last Decade

Daniel J. Figdore

13 papers receiving 208 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel J. Figdore United States 8 112 109 37 29 24 17 213
Jennifer A. Zimmer United States 8 99 0.9× 59 0.5× 44 1.2× 39 1.3× 51 2.1× 18 266
Barbara J. Snider United States 4 125 1.1× 100 0.9× 75 2.0× 22 0.8× 19 0.8× 4 237
Steffi De Meyer Belgium 9 148 1.3× 124 1.1× 58 1.6× 50 1.7× 27 1.1× 17 233
Anthony Fourier France 11 153 1.4× 132 1.2× 96 2.6× 80 2.8× 22 0.9× 25 313
E. van den Berg Netherlands 8 82 0.7× 33 0.3× 41 1.1× 29 1.0× 19 0.8× 16 252
Mohammad Ghofrani Iran 11 87 0.8× 118 1.1× 72 1.9× 23 0.8× 8 0.3× 38 316
Guglielmo Di Molfetta Sweden 7 101 0.9× 89 0.8× 24 0.6× 10 0.3× 11 0.5× 16 147
S. Mastrocola Italy 3 110 1.0× 61 0.6× 20 0.5× 58 2.0× 10 0.4× 3 171
Natalia Ermann Germany 5 187 1.7× 134 1.2× 79 2.1× 78 2.7× 25 1.0× 6 299
Joshua Stevenson‐Hoare United Kingdom 8 138 1.2× 92 0.8× 108 2.9× 22 0.8× 25 1.0× 15 335

Countries citing papers authored by Daniel J. Figdore

Since Specialization
Citations

This map shows the geographic impact of Daniel J. Figdore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel J. Figdore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel J. Figdore more than expected).

Fields of papers citing papers by Daniel J. Figdore

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel J. Figdore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel J. Figdore. The network helps show where Daniel J. Figdore may publish in the future.

Co-authorship network of co-authors of Daniel J. Figdore

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel J. Figdore. A scholar is included among the top collaborators of Daniel J. Figdore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel J. Figdore. Daniel J. Figdore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Ali, Farwa, Jeremy A. Syrjanen, Daniel J. Figdore, et al.. (2025). Association of plasma biomarkers of Alzheimer’s pathology and neurodegeneration with gait performance in older adults. Communications Medicine. 5(1). 19–19. 2 indexed citations
2.
Figdore, Daniel J., et al.. (2025). Differences in Alzheimer's disease blood biomarker stability: Implications for the use of tau/amyloid ratios. Alzheimer s & Dementia. 21(4). e70173–e70173. 4 indexed citations
3.
Bornhorst, Joshua A., Stephen D. Weigand, Daniel J. Figdore, et al.. (2025). Quantitative Assessment of the Effect of Chronic Kidney Disease on Plasma P-Tau217 Concentrations. Neurology. 104(3). e210287–e210287. 12 indexed citations
4.
Figdore, Daniel J., et al.. (2025). Diagnostic performance of plasma p‐tau217 and Aβ42/40 biomarkers in the outpatient memory clinic. Alzheimer s & Dementia. 21(6). e70316–e70316. 4 indexed citations
5.
Figdore, Daniel J., Joshua A. Bornhorst, Jonathan Graff‐Radford, et al.. (2024). Evaluation of Two Plasma pTau217 Simoa Assays Against Amyloid‐PET. Alzheimer s & Dementia. 20(S2).
6.
Figdore, Daniel J., Heather J. Wiste, Joshua A. Bornhorst, et al.. (2024). Performance of the Lumipulse plasma Aβ42/40 and pTau181 immunoassays in the detection of amyloid pathology. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring. 16(1). e12545–e12545. 9 indexed citations
7.
Liu, Danting, John A. Miller, Daniel J. Figdore, et al.. (2024). Elevated neurofilament light chain associated with cobalt/chromium metal neurotoxicity in a patient with a failed hip implant. Clinica Chimica Acta. 567. 120118–120118.
8.
Figdore, Daniel J., et al.. (2024). Head-to-head comparison of four plasma neurofilament light chain (NfL) immunoassays. Clinica Chimica Acta. 561. 119817–119817. 16 indexed citations
9.
Figdore, Daniel J., Michael Griswold, Joshua A. Bornhorst, et al.. (2024). Optimizing cutpoints for clinical interpretation of brain amyloid status using plasma p‐tau217 immunoassays. Alzheimer s & Dementia. 20(9). 6506–6516. 29 indexed citations
10.
Jack, Clifford R., Heather J. Wiste, Alicia Algeciras‐Schimnich, et al.. (2024). Comparison of plasma biomarkers and amyloid PET for predicting memory decline in cognitively unimpaired individuals. Alzheimer s & Dementia. 20(3). 2143–2154. 19 indexed citations
11.
Staff, Nathan P., Björn Oskarsson, Nicolas N. Madigan, et al.. (2024). Results from a Phase 2 Clinical Trial of Repeated Intrathecal Autologous Adipose-derived MSCs in ALS (S5.004). Neurology. 102(7_supplement_1).
12.
Jack, Clifford R., Heather J. Wiste, Alicia Algeciras‐Schimnich, et al.. (2023). Predicting amyloid PET and tau PET stages with plasma biomarkers. Brain. 146(5). 2029–2044. 67 indexed citations
13.
Ramanan, Vijay K., Jonathan Graff‐Radford, Alicia Algeciras‐Schimnich, et al.. (2023). Genetic risk scores enhance the diagnostic value of plasma biomarkers of brain amyloidosis. Brain. 146(11). 4508–4519. 15 indexed citations
14.
Bornhorst, Joshua A., Daniel J. Figdore, Michelle R. Campbell, et al.. (2022). Plasma neurofilament light chain (NfL) reference interval determination in an Age-stratified cognitively unimpaired cohort. Clinica Chimica Acta. 535. 153–156. 28 indexed citations
15.
Figdore, Daniel J., et al.. (2022). Comparison of intact protein and digested peptide techniques for high throughput proteotyping of ApoE. Clinical Proteomics. 19(1). 42–42. 3 indexed citations
16.
Figdore, Daniel J., Michelle R. Campbell, Jeremy A. Syrjanen, et al.. (2022). Analytical Validation of the Quanterix Neurofilament Light Chain (NfL) Advantage Assay in Plasma. Alzheimer s & Dementia. 18(S5).
17.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jennifer A. Zimmer Breakdown of academic impact, for papers by Barbara J. Snider Breakdown of academic impact, for papers by Steffi De Meyer Breakdown of academic impact, for papers by Anthony Fourier Breakdown of academic impact, for papers by E. van den Berg Breakdown of academic impact, for papers by Mohammad Ghofrani Breakdown of academic impact, for papers by Guglielmo Di Molfetta Breakdown of academic impact, for papers by S. Mastrocola Breakdown of academic impact, for papers by Natalia Ermann Breakdown of academic impact, for papers by Joshua Stevenson‐Hoare
Rankless by CCL
2026